-

Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology®

ALASTIN by Galderma, a leader in professional grade skincare, unveils its latest innovation clinically proven to help rejuvenate skin

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, announced today that ALASTIN, a leader in medical-grade peptide-based regenerative skincare, has officially launched their latest skincare innovation with the introduction of Restorative Skin Complex with Next Generation TriHex Technology® (TriHex+™). This newly enhanced formula can be used as a multi-functional, daily rejuvenating serum to support the skin’s natural collagen and elastin production that declines from aging as well as the visible loss of volume in skin impacted by factors such as facial aging or medication-driven weight loss. Restorative Skin Complex with TriHex+ joins ALASTIN’s other world class and award-winning products that are science-led and physician-endorsed.

The much-loved Restorative Skin Complex formula has been enhanced with two groundbreaking additions. The first is an innovation to the patented TriHex Technology with the addition of Octapeptide-45, a proprietary, patent-pending peptide that amplifies the skin’s natural ability to regenerate collagen and elastin addressing the appearance of fine lines, radiance, skin plumping and long-lasting hydration. In addition, the new formula includes a novel ingredient, Magnolol, which helps stimulate depleted fat tissue (adipocytes). These new ingredients help to visibly restore desired facial radiance and plumping by supporting the skin’s own regenerative abilities that decline as we age, especially from age of 25 and up, when we begin losing around 1% of our collagen a year.1

 Galderma’s team is constantly evaluating unmet skin care needs and how we can elevate our products to address them. Concerns like loss of collagen and elasticity, along with the loss of volume as a result of medication-driven weight loss or other factors, have been at the forefront of patient concerns with their skin specialists. We knew we had to do more to help restore their ‘good fat’ while also regenerating the collagen and elastin that can degrade over time.”

 

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS

CHIEF SCIENTIFIC OFFICER GALDERMA, HEAD SKIN SCIENCE
CENTER FOR INNOVATION, HEAD ALASTIN INNOVATIONS

 

ALASTIN will be launching the newly enhanced Restorative Skin Complex with TriHex+ this month in the United States. It will be available exclusively from authorized ALASTIN skincare providers at dermatology offices, clinics and medispas. Galderma is working to bring this new innovation to other international markets where ALASTIN is already available.

 Adding ingredients to further support the appearance of elasticity and skin volumization to a much-loved product that already delivers anti-aging, hydration, and visible volume facial plumping benefits represents a significant clinical and scientific breakthrough.”

 

DEANNE MRAZ, MD, FAAD

PRESIDENT AND FOUNDER, DMR RESEARCH

PRESIDENT AND CO-FOUNDER, MODERN DERMATOLOGY

ASSISTANT CLINICAL PROFESSOR OF DERMATOLOGY, YALE NEW HAVEN HOSPITAL

 

About Galderma

Galderma (SWX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

1 5 Signs Your Skin Is Losing Collagen | Vogue

Contacts

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Jeffrey Smith
Head of U.S. Communications
Jeffrey.smith@galderma.com
+1 (682) 401-8428

Galderma Group AG

SWX:GALD

Release Versions

Contacts

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Jeffrey Smith
Head of U.S. Communications
Jeffrey.smith@galderma.com
+1 (682) 401-8428

More News From Galderma Group AG

Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2025. Net sales: Achieved 1,129 million USD in net sales, up 8.3% year-on-year on a constant currency basis, primarily driven by volume, complemented by favorable mix Results ahead of expectations: Net sales benefited from focused execution, favorable phasing in Injectable Aesthetics, and stronger than expected ramp-up of Neml...

Galderma Launches Sculptra® in China, Further Fueling Its Growth Into One of the Fastest Growing Aesthetics Markets

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced the launch of Sculptra, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation, in China.1-7,11-14 This follows Sculptra’s approval by China’s National Medical Products Administration for correcting mid-facial volume loss and/or contour deficiencies last year. Sculptra – which works with the body’s natural processes to achieve healthier, radiant skin and a more youthful appearance – will no...

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) will showcase a strong presence at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025, with two symposia, four Masterclass sessions, 11 research e-posters, and an experiential Galderma lounge alongside its interactive booth (O2, Hall Ravel) featuring five Meet-the-Expert sessions. This extensive program highlights the breadth of Galderma’s leading Injectable Aesthetics portfolio, designed to...
Back to Newsroom